Records 1 - 21
| Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study.
Cancer medicine 2022 Jun .
Hu Chunhong, Wu Sixuan, Deng Renfang, Wu Yuanqiang, Pan Yue, Shu Long, Wu Fa
| Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma.
Chinese medical journal 2021 Sep 134 (20): 2430-2437.
Liu Xiang-Liang, Bai Ri-Lan, Chen Xiao, Zhao Yu-Guang, Wang Xu, Ma Ke-Wei, Tian Hui-Min, Han Fu-Jun, Liu Zi-Ling, Yang Lei, Li Wei, Gai Fei, Cui Jiu-W
| Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
BMC cancer 2020 Sep 20 (1): 837.
Wang Jing, Liu Zhiyan, Pang Qingsong, Zhang Tian, Chen Xi, Er Puchun, Wang Yuwen, Wang Ping, Wang J
| Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Jul .
Lee Jiyun, La Choi Yoon, Han Joungho, Park Sehhoon, Jung Hyun Ae, Sun Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Park Keunchil, Ahn Myung-
| Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
Asian Pacific journal of cancer prevention : APJCP 2019 Dec 20 (12): 3581-3589.
Incharoen Pimpin, Charonpongsuntorn Chanchai, Saowapa Sakditat, Sirachainan Ekaphop, Dejthevaporn Thitiya, Kampreasart Kaettipong, Trachu Narumol, Muntham Dittapol, Ruengwetwattana Thanyan
| Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.
Radiology and oncology 2019 Nov 53 (4): 453-458.
Stanic Karmen, Turnsek Nina, Vrankar Marti
| Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
Oncology research 2019 Oct .
Xu Jianping, Liu Xiaoyan, Yang Sheng, Shi Yuank
| Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Lung cancer (Amsterdam, Netherlands) 2019 Jul 133 96-102.
Awad Mark M, Leonardi Giulia C, Kravets Sasha, Dahlberg Suzanne E, Drilon Alexander, Noonan Sinead A, Camidge D Ross, Ou Sai-Hong I, Costa Daniel B, Gadgeel Shirish M, Steuer Conor E, Forde Patrick M, Zhu Viola W, Fukuda Yoko, Clark Jeffrey W, Jänne Pasi A, Mok Tony, Sholl Lynette M, Heist Rebecca
| Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.
Cancer management and research 2019 11 5665-5675.
Hou Helei, Qin Kang, Liang Yu, Zhang Chuantao, Liu Dong, Jiang Haiping, Liu Kewei, Zhu Jingjuan, Lv Hongying, Li Tianjun, Zhang Xiaoch
| Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
PloS one 2019 14 (8): e0220691.
Grosse Claudia, Soltermann Alex, Rechsteiner Markus, Grosse Alexand
| Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis.
Lung Cancer (Auckland, N.Z.) 2019 10 1-10.
Kate Shruti, Chougule Anuradha, Joshi Amit, Noronha Vanita, Patil Vijay, Dusane Rohit, Solanki Leena, Tiwrekar Priyanka, Trivedi Vaishakhi, Prabhash Kum
| Cytoplasmic expression of estrogen receptor ß may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma.
Oncology letters 2018 Aug 16 (2): 2382-2390.
Ding Xiaosheng, Li Li, Tang CHuanhao, Meng Chao, Xu Weiran, Wei Xing, Guo Ziwei, Zhang Tingting, Fu Yali, Zhang Lingling, Wang Xiangyi, Lin Li, Liang J
| Lung cancer in never smokers from the Princess Margaret Cancer Centre.
Oncotarget 2018 Apr 9 (32): 22559-22570.
Korpanty Grzegorz J, Kamel-Reid Suzanne, Pintilie Melania, Hwang David M, Zer Alona, Liu Geoffrey, Leighl Natasha B, Feld Ronald, Siu Lillian L, Bedard Philippe L, Tsao Ming-Sound, Shepherd Frances
| Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2018 Mar 117 44-49.
Gerber David E, Socinski Mark A, Neal Joel W, Wakelee Heather A, Shirai Keisuke, Sequist Lecia V, Rosovsky Rachel P, Lilenbaum Rogerio C, Bastos Bruno R, Huang Chao, Johnson Melissa L, Hesketh Paul J, Subramaniam Deepa S, Dietrich Martin F, Chai Feng, Wang Yunxia, Kazakin Julia, Schwartz Brian, Schiller Joan H, Brahmer Julie R, Kelly Ronan
| Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors.
Oncotarget 2017 Sep 8 (41): 70865-70873.
Zhao Xin Min, Zhao Jing, Xing Kai Lin, Sun Si, Luo Zhi Guo, Wang Hui Jie, Wang Jia Lei, Chang Jian Hua, Wu Xiang H
| Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Lung cancer (Amsterdam, Netherlands) 2016 Oct 100 14-9.
Yoshida Tatsuya, Tanaka Hirotaka, Kuroda Hiroaki, Shimizu Junichi, Horio Yoshitsugu, Sakao Yukinori, Inaba Yoshitaka, Iwata Hiroshi, Hida Toyoaki, Yatabe Yasus
| EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.
Cancer biology & therapy 2016 Jan 0.
Que Dan, Xiao He, Zhao Baojian, Zhang Xu, Wang Qiushi, Xiao Hualiang, Wang
| Genetic variants of BCL2 gene predict clinical outcomes of non-small-cell lung cancer patients treated with platinum-based chemotherapy in a Chinese population.
American journal of cancer research 2016 6 (10): 2310-2322.
Ding Xi, Qian Ji, Yang Yang, Xu Wen, Liu Di, Su
| Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.
ESMO open 2016 1 (4): e000063.
Azuma Koichi, Hirashima Tomonori, Yamamoto Nobuyuki, Okamoto Isamu, Takahashi Toshiaki, Nishio Makoto, Hirata Taizo, Kubota Kaoru, Kasahara Kazuo, Hida Toyoaki, Yoshioka Hiroshige, Nakanishi Kaoru, Akinaga Shiro, Nishio Kazuto, Mitsudomi Tetsuya, Nakagawa Kazuhi
| [Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2012 May 35 (5): 323-8.
Duan Jian-chun, An Tong-tong, Wu Mei-na, Yang Lu, Bai Hua, Wang Zhi-jie, Wang Yu-yan, Zhuo Ming-lei, Zhao Jun, Wang Shu-hang, Wang J
| Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications.
Journal of cancer research and therapeutics 0 9 (2): 261-6.
Ovcaricek Tanja, Cufer Tanja, Kern Izidor, Sodja Eva, Sadikov Aleksand